{
    "guideline_identifier": "PIIS0923753424049123.txt",
    "cancer_focus": {
        "primary_cancer": "Cutaneous Melanoma",
        "related_syndrome_or_condition": ""
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Stage I/IIA",
            "risk_group": "Low risk",
            "treatment_plans": [
                {
                    "clinical_context": "Localized Disease (Primary Tumor)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Wide Local Excision (WLE) with margins: in situ: 0.5 cm; ≤2 mm thickness: 1 cm; >2 mm thickness: 2 cm. Radiotherapy only for inoperable cases (e.g., severe comorbidities)",
                    "treatment_line": "Primary treatment",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Stage IIB/IIC",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Localized Disease (Primary Tumor)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Wide Local Excision (WLE) with margins: in situ: 0.5 cm; ≤2 mm thickness: 1 cm; >2 mm thickness: 2 cm",
                    "treatment_line": "Primary treatment",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Adjuvant Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab for 12 months",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I, A"
                }
            ]
        },
        {
            "staging_criteria": "Stage IIIA",
            "risk_group": "Lower risk (≤1 mm SLNB burden)",
            "treatment_plans": [
                {
                    "clinical_context": "Locoregional Disease (Lymph Nodes)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "No complete lymph node dissection (CLND) after positive SLNB; standard follow-up. Adjuvant therapy not standard",
                    "treatment_line": "Post-SLNB management",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                }
            ]
        },
        {
            "staging_criteria": "Stage IIIB–IIID",
            "risk_group": "High risk",
            "treatment_plans": [
                {
                    "clinical_context": "Adjuvant Therapy (Resected)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Anti-PD-1 monotherapy (nivolumab or pembrolizumab) for BRAF wild-type",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF V600",
                            "status": "Wild-type",
                            "testing_guidance": "Mandatory testing before therapy (IHC/NGS)"
                        }
                    ],
                    "esmo_evidence_level": "Level I, A"
                },
                {
                    "clinical_context": "Adjuvant Therapy (Resected)",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Dabrafenib + trametinib for BRAF V600E-mutant",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF V600",
                            "status": "V600E-mutant",
                            "testing_guidance": "Mandatory testing before therapy (IHC/NGS)"
                        }
                    ],
                    "esmo_evidence_level": "Level I, A"
                },
                {
                    "clinical_context": "Neoadjuvant Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nivolumab + ipilimumab for 2 cycles → surgery. Omit adjuvant therapy if major pathological response (MPR)",
                    "treatment_line": "Neoadjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level I, A"
                },
                {
                    "clinical_context": "Neoadjuvant Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Pembrolizumab (neoadjuvant + adjuvant)",
                    "treatment_line": "Neoadjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (NED)",
            "risk_group": "No evidence of disease post-metastasectomy",
            "treatment_plans": [
                {
                    "clinical_context": "Adjuvant Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nivolumab ± ipilimumab",
                    "treatment_line": "Adjuvant",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II"
                }
            ]
        },
        {
            "staging_criteria": "Stage IV (Unresectable/Metastatic)",
            "risk_group": "Advanced disease",
            "treatment_plans": [
                {
                    "clinical_context": "First-Line Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nivolumab + ipilimumab (preferred if feasible)",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "First-Line Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nivolumab + relatlimab for PD-L1 ≥1%",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "PD-L1",
                            "status": "≥1%",
                            "testing_guidance": "Required for EMA approval in unresectable stage III/IV"
                        }
                    ],
                    "esmo_evidence_level": "Level I, B"
                },
                {
                    "clinical_context": "First-Line Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "BRAF/MEK inhibitors (dabrafenib/trametinib or encorafenib/binimetinib) for BRAF V600E/K mutants",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF V600",
                            "status": "V600E/K-mutant",
                            "testing_guidance": "Mandatory testing before therapy (IHC/NGS)"
                        }
                    ],
                    "esmo_evidence_level": "Level I"
                },
                {
                    "clinical_context": "Second-Line Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Ipilimumab ± nivolumab after anti-PD-1 failure",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": ""
                },
                {
                    "clinical_context": "Second-Line Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "TIL therapy (lifileucel) after anti-PD-1 failure",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "Level II, B"
                },
                {
                    "clinical_context": "Second-Line Therapy",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Binimetinib for NRAS-mutant melanoma",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "NRAS",
                            "status": "Mutant",
                            "testing_guidance": "Conditional testing if BRAF wild-type"
                        }
                    ],
                    "esmo_evidence_level": "Level II"
                },
                {
                    "clinical_context": "Brain Metastases Management",
                    "recommendation_type": "Treatment",
                    "recommendation_content": "Nivolumab + ipilimumab or BRAF/MEK inhibitors (for BRAF-mutant) for asymptomatic cases",
                    "treatment_line": "Special population",
                    "biomarker_requirements": [
                        {
                            "name": "BRAF V600",
                            "status": "V600E/K-mutant (for BRAF/MEKi)",
                            "testing_guidance": "Mandatory testing before targeted therapy"
                        }
                    ],
                    "esmo_evidence_level": ""
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "BRAF V600 mutation predicts response to BRAF/MEK inhibitors. PD-L1 expression (≥1%) predicts efficacy of nivolumab/relatlimab. NRAS mutation predicts response to MEK inhibitors (binimetinib). TMB may predict immunotherapy response. GEP signatures (e.g., AMBRA1/loricrin) provide prognostic information in stage I/II."
    }
}